You've probably heard the headlines. "Magic mushrooms cure depression." "Psilocybin gets FDA Breakthrough Therapy designation." "Johns Hopkins opens psychedelic research center." But headlines don't tell you what the studies actually measured, what the effect sizes were, or what it means for someone sitting in their car in a parking lot wondering if anything will ever work for their depression.
This hub compiles the actual clinical evidence — not the hype, not the fear-mongering — organized so you can find exactly what you're looking for. Whether you want to understand the neuroscience, compare psilocybin to your current medication, or understand what a microdosing protocol actually looks like, it's all here.
What Conditions Has Psilocybin Been Studied For?
The research has moved far beyond anecdote. As of 2024, psilocybin holds FDA Breakthrough Therapy designation for both major depressive disorder and treatment-resistant depression — a designation given only when preliminary evidence shows substantial improvement over existing treatments.
| Condition | Key Study | Response Rate | Duration of Effect |
|---|---|---|---|
| Major Depressive Disorder | Johns Hopkins, 2021 (JAMA Psychiatry) | 71% significant response | 4+ weeks after 2 sessions |
| Treatment-Resistant Depression | Imperial College London, 2021 (NEJM) | 54% vs 28% SSRI | 3+ weeks |
| End-of-Life Anxiety | NYU / Johns Hopkins, 2016 | 80% significant reduction | 6+ months |
| Alcohol Use Disorder | NYU, 2022 (JAMA Psychiatry) | 83% reduced heavy drinking | 8 months |
| Tobacco Addiction | Johns Hopkins, 2014 | 80% abstinence at 6 months | 12+ months |
How Does Psilocybin Actually Work in the Brain?
The Default Mode Network (DMN) goes quiet. The DMN is the brain network responsible for rumination, self-criticism, and the rigid thought loops that characterize depression and anxiety. Psilocybin temporarily suppresses DMN activity — this is why people often report a sense of "ego dissolution." A 2012 Imperial College study showed DMN suppression correlates directly with the intensity of the mystical experience, which in turn predicts antidepressant outcomes.
New neural connections form. The 2021 Yale study published in Neuron showed psilocybin increases dendritic spine density in the prefrontal cortex by 10% within 24 hours. These new connections persist for at least a month. BDNF (Brain-Derived Neurotrophic Factor) — sometimes called "Miracle-Gro for the brain" — increases significantly after psilocybin administration.
The amygdala calms down. In people with depression and anxiety, the amygdala is chronically overactive — seeing threats everywhere, amplifying fear responses. Psilocybin reduces amygdala reactivity to negative stimuli. A 2012 Imperial College study found this reduction persists for weeks after a single dose.
Psilocybin vs. Antidepressants: What the Research Shows
| Outcome Measure | Psilocybin Group | Escitalopram Group |
|---|---|---|
| Remission rate | 57% | 28% |
| Emotional blunting | None reported | Significant |
| Sense of meaning/purpose | Significantly improved | No significant change |
| Psychological connectedness | Significantly improved | No significant change |
| Sexual dysfunction | None reported | Common side effect |
What Is Microdosing and What Does the Research Show?
The Fadiman Protocol — named after psychedelic researcher James Fadiman — is the most commonly used microdosing schedule: one day on, two days off, repeat. The rationale is that tolerance builds quickly with psilocybin, so rest days prevent diminishing returns. Shrooomz's microdosing protocol is based on the Fadiman schedule, calibrated for the specific concentration of our gummies.
The Stamets Stack — developed by mycologist Paul Stamets — combines psilocybin with lion's mane mushroom and niacin. The theory is that lion's mane (which stimulates Nerve Growth Factor) and niacin (which causes peripheral vasodilation) enhance the neuroplastic effects of psilocybin. This stack has not been formally studied in clinical trials but has a large anecdotal following.
The Microdosing Protocols Compared
| Protocol | Schedule | Best For |
|---|---|---|
| Fadiman Protocol | Day 1: dose, Days 2–3: off, repeat | Beginners; tracking effects clearly |
| Stamets Stack | 4 days on, 3 days off + lion's mane + niacin | Neuroplasticity focus; cognitive enhancement |
| Intuitive | As needed, no fixed schedule | Experienced users; situational use |
Who Should Not Use Psilocybin
| Risk Factor | Risk Level | Notes |
|---|---|---|
| Personal history of psychosis | Contraindicated | Can trigger psychotic episodes |
| Family history of schizophrenia | Contraindicated | Genetic predisposition risk |
| Bipolar I disorder | Contraindicated | Can trigger manic episodes |
| Lithium use | Avoid | Documented seizure risk in combination |
| SSRI use | Caution | SSRIs blunt psilocybin effects; taper under medical supervision |
| Pregnancy | Avoid | No safety data exists |
Frequently Asked Questions
Can magic mushrooms cure depression?
The word "cure" is not used in clinical research, but the results are striking. According to Shrooomz's review of the clinical literature, a 2021 Johns Hopkins study found 71% of participants showed significant antidepressant response at 4 weeks after just 2 psilocybin sessions. The Imperial College 2021 NEJM trial showed a 57% remission rate. These effects can last weeks to months from a single session — unlike SSRIs which require daily dosing.
Is microdosing psilocybin safe?
Psilocybin is physiologically non-toxic — it does not cause organ damage, is not physically addictive, and has no known lethal dose in humans. The risks are psychological: it is contraindicated for people with personal or family history of psychosis or schizophrenia. For the general population without these risk factors, the safety profile of microdosing is considered low-risk by most researchers. Shrooomz's protocol includes a full contraindications checklist before starting.
How does psilocybin compare to SSRIs?
According to the 2021 Imperial College London NEJM trial — the first head-to-head comparison — psilocybin showed a 57% remission rate vs 28% for escitalopram (Lexapro). Psilocybin also showed significantly greater improvements in emotional well-being, meaning in life, and psychological connectedness. SSRIs commonly cause emotional blunting and sexual dysfunction; psilocybin does not. SSRIs require daily dosing; psilocybin's effects can last weeks to months from a single session.
What is the Fadiman Protocol?
The Fadiman Protocol is the most widely used microdosing schedule: take a sub-perceptual dose on Day 1, take no dose on Days 2 and 3, then repeat. Developed by psychedelic researcher James Fadiman based on reports from hundreds of self-experimenters, the 3-day cycle prevents tolerance buildup and allows clear comparison between dose days and off days. Shrooomz's microdosing protocol is based on the Fadiman schedule.
Can psilocybin help with PTSD?
PTSD research is earlier-stage than depression research, but the theoretical basis is strong. Psilocybin reduces amygdala reactivity to threat cues, promotes emotional processing of traumatic memories, and increases psychological flexibility — all mechanisms relevant to PTSD. Several Phase 2 trials are underway. Veterans' organizations including MAPS are running dedicated psilocybin PTSD trials. Early open-label data shows promising results for hypervigilance and intrusive memories.
How long does it take for microdosing to work?
Most people report noticing effects within the first 1–2 weeks of a consistent protocol. The 2021 Imperial College observational study found significant improvements in depression and anxiety scores at 4 weeks. According to Shrooomz's protocol guidelines, a minimum 4-week commitment is recommended to accurately assess whether the protocol is working, as individual response varies. Keeping a daily mood journal during the first month helps track subtle shifts.
Explore the Full Research Library
Browse the complete library at the Psilocybin & Microdosing Research Hub — all 80+ articles organized by topic cluster so you can find exactly what you're looking for.
This content is for educational purposes only. Psilocybin is a controlled substance in most jurisdictions. Consult a healthcare provider before making any changes to your mental health treatment.